A diverse and interconnected team
Arch Biopartners Scientists and Management teams
The company is led by a team of scientists, executives, board members, and advisors with deep experience in science, pharmaceuticals, biotechnology, and corporate finance.
Arch Biopartners’ scientific leadership brings deep expertise in kidney disease, inflammation biology, and advancing discoveries from the lab to the clinic.
- Dr. Daniel Muruve, Chief Science Officer and Co-Founder, leads the Company’s clinical and translational research, with internationally recognized expertise in kidney disease and inflammation.
- The scientific team includes leading investigators from the University of Calgary, whose discoveries established the dipeptidase-1 (DPEP1) pathway and LSALT Peptide as first-in-class approaches to prevent inflammation-driven kidney injury.
- The addition of Dr. Justin Chun as a Principal Scientist marks Arch Biopartners’ expansion into chronic kidney disease (CKD), advancing a breakthrough platform that targets IL-32 in diabetic kidney disease.
- Executives and Founders, CEO Richard Muruve, CSO Dr. Daniel Muruve MD. and CFO Andrew Bishop form the management team
- Board of Directors, includes a group of key directors and strategic advisors